Who is sponsoring NCT04847726?

NCT04847726 is sponsored by Seoul National University Hospital.

What drugs are being tested in NCT04847726?

Interventions in NCT04847726: contrast enhanced ultrasound, Dynamic CT, Liver MRI.

What condition does NCT04847726 study?

NCT04847726 studies Hepatocellular Carcinoma.

Is NCT04847726 still recruiting?

NCT04847726 is currently completed. Last updated 7 December 2021.

Last reviewed 2021-12-07 · How we verify

NCT04847726

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma

Completed NA Last updated 7 December 2021

What this trial tests

NA trial testing contrast enhanced ultrasound in Hepatocellular Carcinoma in 110 participants. Completed in 30 October 2021.

Timeline

9 June 2020

Primary endpoint
30 July 2021

30 October 2021

Quick facts

Lead sponsor	Seoul National University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	110
Start date	9 June 2020
Primary completion	30 July 2021
Estimated completion	30 October 2021
Sites	1 location across South Korea

Drugs / interventions tested

contrast enhanced ultrasound — full drug profile →
Dynamic CT
Liver MRI

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Seoul National University Hospital

Who can join

18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intra-individual comparison of diagnostic performance of CEUS With perfluorobutane and sulfur hexafluoride for HCC in high-risk Individuals, and their role in the diagnostic algorithm of HCC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sonazoid™ versus SonoVue<sup>®</sup> for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study.
Kang HJ, Lee JM, Yoon JH, Yoo J, et al · · 2022 · cited 21× · PMID 36196767 · DOI 10.3348/kjr.2022.0388

Verify or expand the search:

Other trials of contrast enhanced ultrasound

Trials testing the same drug.

NCT04494022 — Role of CEUS as a Secondary Diagnostic Modality · NA · unknown

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Seoul National University Hospital trials

Trials by the same sponsor.

NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04847726 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
Last refreshed: 7 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04847726.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing